BlackRock reports 8.2% stake in PROCEPT BioRobotics
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BlackRock, Inc. reports its beneficial ownership of common stock of PROCEPT BioRobotics Corp on an amended Schedule 13G. BlackRock and certain of its business units collectively beneficially own 4,646,656 shares of PROCEPT BioRobotics common stock, representing 8.2% of the outstanding class.
BlackRock has sole voting power over 4,558,571 shares and sole dispositive power over all 4,646,656 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have rights to dividends and sale proceeds, but no single person has an interest exceeding five percent of PROCEPT BioRobotics’ outstanding common shares. The filing is signed by Spencer Fleming, Managing Director of BlackRock, Inc.
Key Figures
Key Terms
beneficially owned financial
sole dispositive power financial
sole voting power financial
parent holding company financial
Schedule 13G regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What percentage of PRCT’s common stock is held by BlackRock, Inc.?
Does any other single investor hold over 5% of PRCT through BlackRock’s accounts?
Who signed the PRCT Schedule 13G/A on behalf of BlackRock, Inc.?
Which BlackRock entities are included in this PRCT ownership report?
AI-generated analysis. How Rhea-AI works. Not financial advice.